Stock Track | Moderna Plummets 5.08% Intraday Following $178 Million Patent Settlement Payment

Stock Track07-16

Moderna Inc.'s stock plummeted 5.08% during intraday trading on Thursday, as investors reacted to news of a significant settlement payment related to patent litigation.

The decline comes after Moderna paid $178 million to Arbutus Biopharma earlier this month to resolve patent infringement litigation related to Moderna's Covid-19 vaccines. The settlement agreement was disclosed as Arbutus filed additional patent infringement lawsuits against Pfizer and BioNTech for similar lipid nanoparticle technology.

This substantial payment represents a direct financial cost to Moderna and highlights ongoing legal challenges surrounding intellectual property in the mRNA vaccine space, which appears to have prompted investor concern during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment